Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-200 plus Cytarabine in Refractory or Relapsed Acute Leukemia
NCT02930109Phase 2Completed
- Sponsor
- Prescient Therapeutics
- Start
- Dec 2016
- Primary completion
- Oct 2023
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of triciribine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), sponsored by Prescient Therapeutics. Primary endpoint: Treatment-related Adverse Events at 12 months. Started Dec 2016; status: completed.
02
Drugs
triciribine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02930109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930109.